PMID: 4074453Aug 1, 1985Paper

Chylomicrons from patients with type V hyperlipoproteinemia inhibit platelet function

M AviramJ G Brook


Platelet aggregation and [14C]serotonin release induced by collagen and also by ADP and thrombin were significantly decreased in patients with primary Type V hyperlipoproteinemia. Platelets derived from these patients lost their hyporesponsiveness to thrombin and ADP (but not to collagen) after washings and isolation from their plasma environment. On incubation of platelets derived from normolipidemic controls with plasma derived from patients, platelet aggregation and [14C]serotonin release were lowered by 20% and 30%, respectively. On incubation of these platelets with 100 mg/dl of chylomicron triglyceride, a 40% reduction in both platelet aggregation and [14C]serotonin release was observed. The inhibition of platelet activity was positively correlated with chylomicron concentration up to a concentration of 225 mg/dl by chylomicron triglyceride. In 2 patients, bezafibrate administration (600 mg/day) resulted in marked reduction of plasma triglyceride concentration and a parallel improvement in platelet function. The platelet hyporesponsiveness in patients with Type V hyperlipoproteinemia appears to be a consequence of platelet-chylomicron interaction. This depressed platelet function may be responsible for the absence of over...Continue Reading


Jan 1, 1976·European Neurology·P HarcosJ Pucsok
Sep 1, 1979·Circulation·D B Zilversmit
Aug 19, 1976·The New England Journal of Medicine·R Ross, J A Glomset
Aug 12, 1976·The New England Journal of Medicine·R Ross, J A Glomset
Apr 1, 1985·Lipids·M AviramJ G Brook
Feb 21, 1974·The New England Journal of Medicine·A C CarvalhoR S Lees
Jan 1, 1974·Scandinavian Journal of Haematology·A NordoyK Gjesdal
Aug 1, 1984·Biochemical Medicine·M Aviram, J G Brook
Oct 15, 1983·The Biochemical Journal·D G HassallK R Bruckdorfer
Jun 1, 1984·European Journal of Clinical Investigation·A VienerM Aviram
Mar 1, 1983·Atherosclerosis·M Aviram, J G Brook
Jul 1, 1983·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·D G HassallB Lewis
Mar 1, 1982·The Medical Clinics of North America·J D Brunzell, E L Bierman
Apr 15, 1982·Thrombosis Research·M Aviram, G J Brook
Mar 16, 1981·Biochemical and Biophysical Research Communications·M AviramR S Lees
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON

❮ Previous
Next ❯


Aug 14, 1995·Clinica Chimica Acta; International Journal of Clinical Chemistry·R KnöflerA Takada
Jan 1, 1992·Molecular Aspects of Medicine·C Rice-Evans, K R Bruckdorfer
Mar 16, 2002·The British Journal of Nutrition·Jonathan M HodgsonShin-Yee Chan
Jul 1, 1987·Progress in Cardiovascular Diseases·M Aviram, J G Brook
Apr 1, 1989·Metabolism: Clinical and Experimental·M Aviram, R J Deckelbaum
Dec 1, 1989·Prostaglandins, Leukotrienes, and Essential Fatty Acids·K R Bruckdorfer
Jul 1, 1989·Prostaglandins, Leukotrienes, and Essential Fatty Acids·J NimpfG M Kostner
Jun 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·N XuA Nilsson

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.